MGFA Study Web Content:

RVT-1401-2002: A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of RVT-1401 in Myasthenia Gravis Patients

**Study Purpose:** The purpose of the current study is to assess safety/tolerability and key pharmacodynamic (PD) effects that are considered to be associated with clinical benefit (reduction of total IgG and anti-AChR-IgG) in Myasthenia Gravis patients treated with RVT-1401 (also known as IMVT-1401).

**Recruitment Information:**

**Study Type:** Interventional (Clinical Trial)

**Status:** Recruiting

**Target Patient:** AChR Positive Patients

**Eligible Ages:** 18 Years and older

**Link to appropriate websites** [https://www.clinicaltrials.gov/ct2/show/NCT03863080?term=RVT-1401&rank=2](https://www.clinicaltrials.gov/ct2/show/NCT03863080?term=RVT-1401&rank=2)

**Inclusion and Exclusion Criteria:**

**Inclusion Criteria:** 1. Male or female ≥ 18 years of age. 2. Myasthenia Gravis Foundation of America (MGFA) Class II-IVa and likely not in need of a respirator for the duration of the study as judged by the Investigator. 3. QMG score ≥12 at Screening and Baseline. 4. Other, more specific inclusion criteria are defined in the protocol.

**Exclusion Criteria:** 1. Use of rituximab, belimumab, eculizumab or any monoclonal antibody for immunomodulation within 6 months prior to first dosing. 2. Immunoglobulins given by SC, IV (IVIG), or intramuscular route, or plasmapheresis/plasma exchange (PE) within 4 weeks before Screening. 3. Thymectomy performed < 12 months prior to screening. 4. Total IgG level <6 g/L (at screening). 5. Absolute neutrophil count <1500 cells/mm3(at screening). 6. Other, more specific exclusion criteria are defined in the protocol.
Study Information:

Sponsor: Immunovant Sciences GmbH

Principal Investigator: Vera Bril, MD

Study Coordinator: Click here to enter text.

Type of Study: Phase 2a

Study Duration: Screening period is up to 21 days. If subject is enrolled, the duration of subject participation is 18 weeks.

Single Center/Multi-center: Multi-Center

Travel Funds Available: ☒ Y ☐ N

Study Contact: clinicaltrials@immunovant.com
               1-800-797-0414

Find A Center Near You:

List Sites Here

United States, Alabama
IMC/Diagnostic & Medical Clinic
Mobile, Alabama, United States, 36604
Principal Investigator: Dr. John Hinton

United States, Arizona
Phoenix Neurological Associates
Phoenix, Arizona, United States, 85018
Principal Investigator: Dr. Todd Levine

United States, Connecticut
Yale School of Medicine, Department of Neurology
New Haven, Connecticut
Principal Investigator: Dr. Richard Nowak

United States, California
UC Irvine - MDA ALS and Neuromuscular Center
Orange, California, United States, 92868
Principal Investigator: Dr. Ali Habib

United States, Minnesota
University of Minnesota – Department of Neurology
Minneapolis, Minnesota, United States, 55455
Principal Investigator: Dr. Jeffrey Allen

United States, New York
University of Buffalo
Buffalo, New York, United States, 14260-1660
Principal Investigator: Nicholas Silvestri
Hospital for Special Surgery, Neurology Belaire Building
New York, New York, United States, 10021
Principal Investigator: Dr. Dale Lange

United States, Pennsylvania
Allegheny Neurological Associates
Pittsburgh, PA, United States, 15212
Principal Investigator: Dr. George Small

United States, Texas
UTSW James W. Aston Ambulatory Care Center - Neurology Clinic
Dallas, Texas, United States, 75390
Principal Investigator: Dr. Shaida Khan

Canada, Alberta
University of Alberta Hospitals - Division of Pulmonary Medicine
Edmonton, Alberta, Canada, T6G 2G3
Principal Investigator: Dr. Zaeem Siddiqi

Canada, Ontario
London Health Sciences Centre
London, Ontario, Canada, N6G 2V4
Principal Investigator: Dr. Michael Nicolle

Ottawa Hospital Research Institute
Ottawa, Ontario, Canada, K1Y 4E9
Principal Investigator: Dr. Ari Breiner

University Health Network Toronto General Hospital
Toronto, Ontario, Canada, M5G 2C4
Principal Investigator: Dr. Vera Bril

Canada, Quebec

Montreal Neurological Institute and Hospital
Montreal, Quebec, Canada, H3A 2B4
Principal Investigator: Dr. Angela Genge